These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 22406516)

  • 41. The immune network in pancreatic cancer development and progression.
    Wörmann SM; Diakopoulos KN; Lesina M; Algül H
    Oncogene; 2014 Jun; 33(23):2956-67. PubMed ID: 23851493
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
    Ibrahim AM; Wang YH
    World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy.
    Smith C; Zheng W; Dong J; Wang Y; Lai J; Liu X; Yin F
    World J Gastroenterol; 2022 Jul; 28(27):3297-3313. PubMed ID: 36158269
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
    Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H
    Front Immunol; 2018; 9():1878. PubMed ID: 30158932
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cellular determinants and therapeutic implications of inflammation in pancreatic cancer.
    Stone ML; Beatty GL
    Pharmacol Ther; 2019 Sep; 201():202-213. PubMed ID: 31158393
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas: The Cancer Immunity Cycle.
    Kieler M; Unseld M; Bianconi D; Prager G
    Pancreas; 2018 Feb; 47(2):142-157. PubMed ID: 29346215
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Harnessing the Microbiome for Pancreatic Cancer Immunotherapy.
    Vitiello GA; Cohen DJ; Miller G
    Trends Cancer; 2019 Nov; 5(11):670-676. PubMed ID: 31735286
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer.
    Hegde S; Krisnawan VE; Herzog BH; Zuo C; Breden MA; Knolhoff BL; Hogg GD; Tang JP; Baer JM; Mpoy C; Lee KB; Alexander KA; Rogers BE; Murphy KM; Hawkins WG; Fields RC; DeSelm CJ; Schwarz JK; DeNardo DG
    Cancer Cell; 2020 Mar; 37(3):289-307.e9. PubMed ID: 32183949
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current Status of Immunotherapies for Treating Pancreatic Cancer.
    Wu AA; Jaffee E; Lee V
    Curr Oncol Rep; 2019 May; 21(7):60. PubMed ID: 31101991
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel and emerging innate immune therapeutic targets for pancreatic cancer.
    Wang L; Shureiqi I; Stroehlein JR; Wei D
    Expert Opin Ther Targets; 2018 Dec; 22(12):977-981. PubMed ID: 30332892
    [No Abstract]   [Full Text] [Related]  

  • 51. The Unique Microbiome and Immunity in Pancreatic Cancer.
    Wei X; Mei C; Li X; Xie Y
    Pancreas; 2021 Feb; 50(2):119-129. PubMed ID: 33565788
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.
    Jindal V; Arora E; Masab M; Gupta S
    Med Oncol; 2018 May; 35(6):84. PubMed ID: 29728788
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Characteristics of pancreatic ductal adenocarcinoma immune microenvironment and related immunotherapy strategies].
    Yuan M; Abuduhaibaier S; Ren SQ; Zheng ZHENG; Yuan CH
    Zhonghua Yi Xue Za Zhi; 2021 Mar; 101(12):831-835. PubMed ID: 33789362
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pancreatic Stellate Cells Promote Tumor Progression by Promoting an Immunosuppressive Microenvironment in Murine Models of Pancreatic Cancer.
    Li C; Cui L; Yang L; Wang B; Zhuo Y; Zhang L; Wang X; Zhang Q; Zhang S
    Pancreas; 2020 Jan; 49(1):120-127. PubMed ID: 31856087
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy of pancreatic cancer.
    Sunami Y; Kleeff J
    Prog Mol Biol Transl Sci; 2019; 164():189-216. PubMed ID: 31383405
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A quantitative score of immune cell infiltration predicts the prognosis in pancreatic ductal adenocarcinoma.
    Chen ZG; Wang Y; Fong WP; Hu MT; Liang JY; Wang L; Li YH
    Int Immunopharmacol; 2021 Sep; 98():107890. PubMed ID: 34174701
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
    Sun H; Zhang B; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses.
    Strauss J; Alewine C; Figg WD; Duffy A
    Clin Transl Oncol; 2016 Jul; 18(7):653-9. PubMed ID: 26661112
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Immune Microenvironment in Pancreatic Cancer.
    Huber M; Brehm CU; Gress TM; Buchholz M; Alashkar Alhamwe B; von Strandmann EP; Slater EP; Bartsch JW; Bauer C; Lauth M
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33022971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.